TheraRadar
← Back
Data updated: Jul 17, 2026

IMMEDICA PHARMA AB

Biotech
Pharmaceuticals

IMMEDICA PHARMA AB is a biotechnology company with 1 FDA-approved products.

2026
Since
1
Drugs
-
Trials
1
New Drugs (2yr)

IMMEDICA PHARMA AB's Key Drugs

IMMEDICA PHARMA AB's core commercial portfolio centers on LOARGYS — its most strategically important drugs approved in the last 15 years.

LOARGYS
Oncology
Approved 2026

IMMEDICA PHARMA AB's Recent FDA Approvals

IMMEDICA PHARMA AB secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

LOARGYS BLA
2026-02-23
pegzilarginase-nbln
1 INDICATIONS AND USAGE LOARGYS is indicated for the treatment of hyperargininemia in adult and pediatric patients 2 years of age and older with Arginase 1 Deficiency (ARG1-D), in conjunction with dietary protein restriction. This indication is approved under accelerated approval based on reduction of plasma arginine [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. LOARGYS is an arginine specific enzyme indicated for the treatment of hyperargininemia in adult and pediatric patients 2 years of age and older with Arginase 1 Deficiency (ARG1-D), in conjunction with dietary protein restriction. ( 1 ) This indication is approved under accelerated approval based on reduction of plasma arginine. ( 14 ) Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ( 1 )

IMMEDICA PHARMA AB's Therapeutic Areas

Disease areas where IMMEDICA PHARMA AB has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

IMMEDICA PHARMA AB Pipeline Snapshot

Active clinical trials for IMMEDICA PHARMA AB across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • LOARGYS leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling